Jay S Patel1, Youngha Oh2, Kevin L Rand1, Wei Wu1, Melissa A Cyders1, Kurt Kroenke3,4,5, Jesse C Stewart1. 1. Department of Psychology, Indiana University-Purdue University Indianapolis (IUPUI), Indianapolis, Indiana. 2. Department of Educational Psychology and Leadership, Research, Evaluation, Measurement, and Statistics (REMS), Texas Tech University, Lubbock, Texas. 3. VA Health Services Research and Development Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, Indiana. 4. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 5. Regenstrief Institute, Indianapolis, Indiana.
Abstract
BACKGROUND: Despite its popularity, little is known about the measurement invariance of the Patient Health Questionnaire-9 (PHQ-9) across U.S. sociodemographic groups. Use of a screener shown not to possess measurement invariance could result in under/over-detection of depression, potentially exacerbating sociodemographic disparities in depression. Therefore, we assessed the factor structure and measurement invariance of the PHQ-9 across major U.S. sociodemographic groups. METHODS: U.S. population representative data came from the 2005-2016 National Health and Nutrition Examination Survey (NHANES) cohorts. We conducted a measurement invariance analysis of 31,366 respondents across sociodemographic factors of sex, race/ethnicity, and education level. RESULTS: Considering results of single-group confirmatory factor analyses (CFAs), depression theory, and research utility, we justify a two-factor structure for the PHQ-9 consisting of a cognitive/affective factor and a somatic factor (RMSEA = 0.034, TLI = 0.985, CFI = 0.989). On the basis of multiple-group CFAs testing configural, scalar, and strict factorial invariance, we determined that invariance held for sex, race/ethnicity, and education level groups, as all models demonstrated close model fit (RMSEA = 0.025-0.025, TLI = 0.985-0.992, CFI = 0.986-0.991). Finally, for all steps ΔCFI was <-0.004, and ΔRMSEA was <0.01. CONCLUSIONS: We demonstrate that the PHQ-9 is acceptable to use in major U.S. sociodemographic groups and allows for meaningful comparisons in total, cognitive/affective, and somatic depressive symptoms across these groups, extending its use to the community. This knowledge is timely as medicine moves towards alternative payment models emphasizing high-quality and cost-efficient care, which will likely incentivize behavioral and population health efforts. We also provide a consistent, evidence-based approach for calculating PHQ-9 subscale scores.
BACKGROUND: Despite its popularity, little is known about the measurement invariance of the Patient Health Questionnaire-9 (PHQ-9) across U.S. sociodemographic groups. Use of a screener shown not to possess measurement invariance could result in under/over-detection of depression, potentially exacerbating sociodemographic disparities in depression. Therefore, we assessed the factor structure and measurement invariance of the PHQ-9 across major U.S. sociodemographic groups. METHODS: U.S. population representative data came from the 2005-2016 National Health and Nutrition Examination Survey (NHANES) cohorts. We conducted a measurement invariance analysis of 31,366 respondents across sociodemographic factors of sex, race/ethnicity, and education level. RESULTS: Considering results of single-group confirmatory factor analyses (CFAs), depression theory, and research utility, we justify a two-factor structure for the PHQ-9 consisting of a cognitive/affective factor and a somatic factor (RMSEA = 0.034, TLI = 0.985, CFI = 0.989). On the basis of multiple-group CFAs testing configural, scalar, and strict factorial invariance, we determined that invariance held for sex, race/ethnicity, and education level groups, as all models demonstrated close model fit (RMSEA = 0.025-0.025, TLI = 0.985-0.992, CFI = 0.986-0.991). Finally, for all steps ΔCFI was <-0.004, and ΔRMSEA was <0.01. CONCLUSIONS: We demonstrate that the PHQ-9 is acceptable to use in major U.S. sociodemographic groups and allows for meaningful comparisons in total, cognitive/affective, and somatic depressive symptoms across these groups, extending its use to the community. This knowledge is timely as medicine moves towards alternative payment models emphasizing high-quality and cost-efficient care, which will likely incentivize behavioral and population health efforts. We also provide a consistent, evidence-based approach for calculating PHQ-9 subscale scores.
Authors: Floriana S Luppino; Leonore M de Wit; Paul F Bouvy; Theo Stijnen; Pim Cuijpers; Brenda W J H Penninx; Frans G Zitman Journal: Arch Gen Psychiatry Date: 2010-03
Authors: Jon D Elhai; Ateka A Contractor; Marijo Tamburrino; Thomas H Fine; Marta R Prescott; Edwin Shirley; Phillip K Chan; Renee Slembarski; Israel Liberzon; Sandro Galea; Joseph R Calabrese Journal: Psychiatry Res Date: 2012-06-12 Impact factor: 3.222
Authors: P K Crane; L E Gibbons; J H Willig; M J Mugavero; S T Lawrence; J E Schumacher; M S Saag; M M Kitahata; H M Crane Journal: AIDS Care Date: 2010-07
Authors: Felix Fischer; Brooke Levis; Carl Falk; Ying Sun; John P A Ioannidis; Pim Cuijpers; Ian Shrier; Andrea Benedetti; Brett D Thombs Journal: Psychol Med Date: 2021-02-22 Impact factor: 10.592
Authors: Jesse C Stewart; Brittanny M Polanka; Kaku A So-Armah; Jessica R White; Samir K Gupta; Suman Kundu; Chung-Chou H Chang; Matthew S Freiberg Journal: Psychosom Med Date: 2020-06 Impact factor: 3.864
Authors: Amy M Sitapati; Barbara Berkovich; April Moreno Arellano; Angela Scioscia; Lawrence S Friedman; Marlene Millen; Patricia Maysent; Ming Tai-Seale; Christopher A Longhurst Journal: JAMIA Open Date: 2020-06-28